Adynxx Inc., of San Francisco, said it received notice of an award for $602,516 from the National Institute on Neurological Disease and Stroke, an NIH institute, to support development of AYX-2 to treat chronic pain. The non-opioid candidate is a transcription factor decoy targeting the activity of certain members of the Krüppel-like family of transcription factors.